- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 11 - Clinical Guidelines Vital to the Future of MS
Emphasizing the need for clinical guidelines for the treatment of multiple sclerosis (MS), Leslie Fish, PharmD, explains that national guidelines would be helpful when determining the appropriateness of first-line versus second-line therapy.
Dr Fish believes that national guidelines would provide helpful information about treatment effectiveness, and could define which agents should be recommended as second-line therapy based on their side effects.
Gary M. Owens, MD, recognizes that there is no single preferred agent for the treatment of MS and clinicians have fallen into a poor trend as they commonly recommend the most popular options as first-line treatment.
For this reason, there is hesitancy from insurers and clinicians about utilizing newer oral agents for treatment. Dr Owens believes that this issue needs to be addressed, especially as new agents continue to develop.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Eliminating Enhanced PTCs Would Have Cascading Economic Impacts, Report Estimates
March 6th 2025Enhanced premium tax credits (PTCs) have made marketplace health insurance more affordable, and eliminating them could have sweeping impacts on consumers and the health care industry, according to a new report.
Read More
